The activation of PI3K/Akt signaling in cancer and its ability to exert chemoresistance led to the development of small molecule inhibitors of PI3K and Akt, which are currently being tested in clinical trials (Kim et al., 2005; Zhang et al., 2017; Zheng, 2017). This evidence concerns the gene AKT1 and cancer.